EBS combines deep value (2.8x forward P/E, 60% FCF yield) and a strong recent earnings-beat streak with heavy short interest, elevated put/call positioning, and modest insider selling that keep sentiment cautious.
Thesis pillars
- Deep Value Strong Fcf Yield→Stable
- Strong Recent Earnings Beats→Stable
- High Short Interest Put Call↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Emergent BioSolutions Inc. (EBS) Stock Analysis
Falling Knife setup · Catalyst-Driven edge
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $7.42, but acceptable to hold if already in. Reasons: Concentration risk — Customer: U.S. Government (USG); Concentration risk — Supplier: sole-source suppliers.
Emergent BioSolutions is a global life sciences company providing medical countermeasures for public health threats — including smallpox, mpox, anthrax, Ebola, and opioid overdose emergencies — organized into a Commercial Products segment (NARCAN® and KLOXXADO® naloxone nasal... Read more
Hold if already holding. Not a fresh buy at $7.42, but acceptable to hold if already in. Reasons: Concentration risk — Customer: U.S. Government (USG); Concentration risk — Supplier: sole-source suppliers. Chart setup: Death cross, below all MAs, RSI 30, MACD bearish. Market cap $375M below $400M minimum. Not in investable universe. Score 4.5/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
About Emergent BioSolutions Inc.
About Emergent BioSolutions Inc.
Emergent BioSolutions maintains an 11-product portfolio addressing global public-health threats such as smallpox, mpox, anthrax, Ebola, and opioid overdose, organized into a Commercial Products segment built around NARCAN and KLOXXADO naloxone nasal sprays and an MCM Products segment supplying anthrax vaccines (BioThrax, CYFENDUS) and smallpox countermeasures (ACAM2000, TEMBEXA) to the U.S. government.
The U.S. Government is Emergent's principal MCM customer, funding development and procurement through multi-year contracts with BARDA, HHS, and the Department of War that can run into the hundreds of millions to billions of dollars — including an ACAM2000 contract valued at up to $2.0 billion over ten years and a BAT antitoxin contract valued at up to $550.0 million. These contracts are typically structured with a base period followed by annual government-exercised options, giving the USG broad discretion over whether and when to fund continued procurement. Commercially, NARCAN Nasal Spray is sold over-the-counter and via standing-order prescriptions to retail pharmacies, health departments, and law enforcement agencies, while KLOXXADO, acquired from Hikma, extends the naloxone portfolio under prescription. The company also provides contract development and manufacturing to external government, pharmaceutical, and non-government-organization customers, though it has substantially reduced this segment's footprint through multiple facility divestitures and closures since 2023.
Show full overview
Emergent's revenue is structurally tied to annual U.S. government appropriations rather than commercial demand: the 10-K states the USG can decline to exercise contract options, redirect Strategic National Stockpile priorities, or terminate procurement agreements for convenience, and that a substantial portion of revenue has come from a concentrated set of USG-procured products. The company's ACAM2000 smallpox vaccine illustrates this exposure directly — the USG chose not to exercise its 2022 option year, then resumed exercising annual extensions from 2023 through 2025 at declining dollar values ($120.0 million, $99.9 million, and $56.0 million, respectively).
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Emergent BioSolutions Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-27Recent Developments — Emergent BioSolutions Inc.
Latest news
- NEWS 'White House Adds Pandemic Response Staff as Ebola Cases Rise' - Bloomberg News — benzinga Jul 1, 2026 neutral
- NEWS Emergent BioSolutions Secures $52.7M U.S. Government Contract Modification For ACAM2000 Smallpox And Mpox Vaccine Supply — benzinga Jun 29, 2026 positive
Generated 2026-07-27T17:02:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerU.S. Government (USG)10-K Item 1A: 'The USG is the principal customer for our MCMs and the primary source of funds for the development of most of our product candidates in our development pipeline.'
- HIGHSuppliersole-source suppliers10-K Item 1A: 'The loss of sole-source suppliers or an increase in the price of inventory.'
Material Events(8-K, last 90d)
- 2026-04-17Item 1.01MEDIUMEmergent BioSolutions entered a Term Loan Agreement on April 16, 2026 with OrbiMed Royalty & Credit Opportunities V, LP as administrative agent, comprising a $150 million initial term loan drawn in full at closing and a $75 million delayed draw facility available for 24 months, subject to a 1.75:1.00 secured leverage ratio covenant.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers·1 ceiling hit
Revenue shrinking — -29.7% YoY. Growth thesis broken unless recovery story develops.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -1.3%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $7.42, but acceptable to hold if already in. Reasons: Concentration risk — Customer: U.S. Government (USG); Concentration risk — Supplier: sole-source suppliers. Chart setup: Death cross, below all MAs, RSI 30, MACD bearish. Market cap $375M below $400M minimum. Not in investable universe. Target $10.20 (+37.5%), stop $7.02 (−5.7%), A.R:R 4.9:1. Score 4.5/10, moderate confidence.
Take-profit target: $10.20 (+37.6% upside). Target $10.20 (+37.5%), stop $7.02 (−5.7%), A.R:R 4.9:1. Stop-loss: $7.02.
Concentration risk — Customer: U.S. Government (USG); Concentration risk — Supplier: sole-source suppliers; Market cap $375M below $400M minimum.
Emergent BioSolutions Inc. trades at a P/E of N/A (forward 2.4). TrendMatrix value score: 9.8/10. Verdict: Hold.
6 analysts cover EBS with a consensus score of 4.0/5. Average price target: $12.
What does Emergent BioSolutions Inc. do?Emergent BioSolutions is a global life sciences company providing medical countermeasures for public health threats —...
Emergent BioSolutions is a global life sciences company providing medical countermeasures for public health threats — including smallpox, mpox, anthrax, Ebola, and opioid overdose emergencies — organized into a Commercial Products segment (NARCAN® and KLOXXADO® naloxone nasal sprays), an MCM Products segment, and a Bioservices contract manufacturing business. Revenue is derived primarily from U.S. government procurement contracts for its medical countermeasure products, supplemented by commercial naloxone sales and non-dilutive R&D grants.